HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors

Molecular Pain

Volumn 10, Issue 1, 2014, Pages

  Zammataro, Magda ^a   Sortino, Maria Angela ^a   Parenti, Carmela ^a   Gereau, Robert W ^b   Chiechio, Santina ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Curcumin; Epigenetic modulation; HAT; HDAC; Inflammatory pain; MGlu2

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; CURCUMIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; METABOTROPIC RECEPTOR 2; VORINOSTAT; AMINO ACID; AMINO ACID RECEPTOR STIMULATING AGENT; FUSED HETEROCYCLIC RINGS; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; METABOTROPIC RECEPTOR;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PAIN MEASUREMENT; SPINAL CORD;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; GANGLIA, SPINAL; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; MICE; PAIN MEASUREMENT; RECEPTORS, METABOTROPIC GLUTAMATE; SPINAL CORD;

EID: 84944037585     PISSN: 17448069     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-10-68     Document Type: Article

References (39)

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
2. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403:41-45.
3. Spange S, Wagner T, Heinzel T, Krämer OH: Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41:185-198.
4. Chiechio S, Copani A, Nicoletti F, Gereau RW 4th: L-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies. Curr Neuropharmacol 2006, 4(3):233-237.
5. Chiechio S, Zammataro M, Morales ME, Busceti CL, Drago F, Gereau RW 4th, Copani A, Nicoletti F: Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 2009, 75(5):1014-1020.
6. Chiechio S, Copani A, Zammataro M, Battaglia G, Gereau RW 4th, Nicoletti F: Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010, 31(4):153-160.
7. Bai G, Wei D, Zou S, Ren K, Dubner R: Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain 2010, 6:51.
8. Chiechio S, Copani A, Gereau RW 4th, Nicoletti F: Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 2007, 21(1):31-38.
9. Chiechio S, Caricasole A, Barletta E, Storto M, Catania MV, Copani A, Vertechy M, Nicolai R, Calvani M, Melchiorri D, Nicoletti F: L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol 2002, 61(5):989-996.
10. Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW 4th: Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006, 2:20.
11. Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ: Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med 2011, 17(11):1448-1455.
12. Denk F, Huang W, Sidders B, Bithell A, Crow M, Grist J, Sharma S, Ziemek D, Rice AS, Buckley NJ, McMahon SB: HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain. Pain 2013, 154(9):1668-1679.
13. Kukkar A, Singh N, Jaggi AS: Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats. J Formos Med Assoc 2013, S0929-6646(13):00180.
14. Matsushita Y, Araki K, Omotuyi O, Mukae T, Ueda H: HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model. Br J Pharmacol 2013, 170(5):991-998.
15. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK: Curcumin, a novel p300/CREB-binding proteinspecific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004, 279:51163-51171.
16. Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ: Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology 2008, 373:239-247.
17. Puglia C, Frasca G, Musumeci T, Rizza L, Puglisi G, Bonina F, Chiechio S: Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. Eur J Pharm Biopharm 2012, 81:288-293.
18. Ma J, Liu J, Yu H, Wang Q, Chen Y, Xiang L: Curcumin promotes nerve regeneration and functional recovery in rat model of nerve crush injury. Neurosci Lett 2013, 547:26-31.
19. Zammataro M, Chiechio S, Montana MC, Traficante A, Copani A, Nicoletti F, Gereau RW IV: mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol Pain 2011, 7:6.
20. Neugebauer V, Chen PS, Willis WD: Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate STT cells. J Neurophysiol 2000, 84(6):2998-3009.
21. Sharpe EF, Kingston AE, Lodge D, Monn JA, Headley PM: Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br J Pharmacol 2002, 135(5):1255-1262.
22. Simmons RM, Webster AA, Kalra AB, Iyengar S: Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 2002, 73(2):419-427.
23. Yang D, Gereau RW 4th: Peripheral group II metabotropic glutamate receptors (mGluR2/3) regulate prostaglandin E2-mediated sensitization of capsaicin responses and thermal nociception. J Neurosci 2002, 22:6388-6393.
24. Yang D, Gereau RW 4th: Peripheral group II metabotropic glutamate receptors mediate endogenous anti-allodynia in inflammation. Pain 2003, 106:411-417.
25. Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE: Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 2005, 1:206-218.
26. Janknecht R: The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 2002, 17:657-668.
27. Zhou H, Beevers CS, Huang S: The targets of curcumin. Curr Drug Targets 2011, 12(3):332-347.
28. Carlton SM, Hargett GL, Coggeshall RE: Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. Neuroscience 2001, 105:957-969.
29. Hanson JE, La H, Plise E, Chen YH, Ding X, Hanania T, Sabath EV, Alexandrov V, Brunner D, Leahy E, Steiner P, Liu L, Scearce-Levie K, Zhou Q: SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One 2013, 8(7):e69964.
30. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF, Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, González-Maeso J: HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012, 15(9):1245-1254.
31. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F: L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 2013, 110(12):4804-4809.
32. Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, Grilli M: Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology 2013, 8(11):2220-2230.
33. Giles RH, Peters DJ, Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998, 14:178-183.
34. Goodman RH, Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 2000, 14:1553-1577.
35. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D, Bhattacharya A, Chattopadhyay S, Das T, Sa G: Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 2011, 286(49):42232-42247.
36. Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999, 27:486-494.
37. Chiechio S, Nicoletti F: Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol 2012, 12(1):28-34.
38. Zhu XY, Huang CS, Li Q, Chang RM, Song ZB, Zou WY, Guo QL: p300 exerts an epigenetic role in chronic neuropathic pain through its acetyltransferase activity in rats following chronic constriction injury (CCI). Mol Pain 2012, 8:26-84.
39. Han YK, Lee SH, Jeong HJ, Kim MS, Yoon MH, Kim WM: Analgesic effects of intrathecal curcumin in the rat formalin test. Korean J Pain 2012, 25(1):1-6.